Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15224


The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory markers, vascular markers and bone development in overweight adolescent females with polycystic ovary syndrome (PCOS).

Study summary:

The purpose of this study is to: 1) to compare effects of treatment with drospirenone/ethinyl estradiol (Yasmin)versus rosiglitazone (Avandia) on hyperandrogenism, insulin resistance/hyperinsulinemia, adrenal hyperresponsiveness, body composition, chronic inflammation, bone mass and turnover. OCPs are the first-line therapy for PCOS, however, they do not address the insulin resistance or the inflammation. Insulin sensitizers have been used successfully to treat PCOS but thiazolidinediones such as rosiglitazone have not been used in adolescents. Therefore we will investigate the effects of treatment with drospirenone/ethinyl estradiol versus rosiglitazone in overweight adolescents with PCOS. We will obtain comprehensive evaluations before and 6 months after randomization, to the respective treatment arms to determine the differences between the 2 treatment modalities.


Inclusion Criteria: - Age 10 - 20 years - Pubertal level of Tanner stage III-V and menarchal - BMI percentile for age and sex greater than or equal to 85%ile Exclusion Criteria: - Oral medications for PCOS, or that have impact on bone (i.e. anti-epileptics) - Presence of other diseases, systemic or psychiatric, or chronic medications which could interfere with endocrine function - Established diagnosis of diabetes - Prior bone surgery, prior osteoporotic fracture, or fracture in the past 12 months - Prior thromboembolic event, such as a deep venous thrombosis or pulmonary embolism (PCOS subjects only) - Vitamin D deficiency (<10ng/mL) - Hyperkalemia (K>5.0 meq/L) - Positive pregnancy test (serum)



Primary Contact:

Principal Investigator
Silva Arslanian, M.D.
University of Pittsburgh

Backup Contact:


Location Contact:

Pittsburgh, Pennsylvania 15224
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.